# Cabergoline

```text
DRUG INFORMATION

  ADULT
    - ( 2.1 ) Recommended starting dosage of cabergoline tablets is 0.25 mg orally twice
      weekly.
      Source: US FDA label for cabergoline (Cabergoline), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.2 ) Titrate cabergoline tablets to achieve normal serum prolactin levels by
      increasing cabergoline tablets by 0.25 mg orally twice weekly at intervals of no
      less than 4 weeks.
      Source: US FDA label for cabergoline (Cabergoline), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.2 ) Maximum recommended dosage is 1 mg orally, twice weekly.
      Source: US FDA label for cabergoline (Cabergoline), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Safety and effectiveness of cabergoline tablets in pediatric patients have not
      been established.
      Source: US FDA label for cabergoline (Cabergoline), section 'pediatric use',
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - ( 5.1 ) Pleural, Pulmonary and Retroperitoneal Fibrosis : During cabergoline
      tablets treatment monitor for signs and symptoms of progressive fibrosis, (e.g.,
      pleuro-pulmonary disease, renal impairment, ureteral/abdominal vascular
      obstruction).
      Source: US FDA label for cabergoline (Cabergoline), section 'warnings and
      cautions', retrieved 2026-08-29
    - Renal impairment or ureteral/abdominal vascular obstruction (e.g., pain in the
      loin/flank, lower limb edema, abdominal masses or tenderness that may indicate
      retroperitoneal fibrosis).
      Source: US FDA label for cabergoline (Cabergoline), section 'warnings and
      cautions', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Avoid use of cabergoline tablets for the inhibition or suppression of physiologic
      lactation [see Indications and Usage ( 1 ) and Warnings and Precautions ( 5 . 4 )]
      . 8.4 Pediatric Use Safety and effectiveness of cabergoline tablets in pediatric
      patients have not been established.
      Source: US FDA label for cabergoline (Cabergoline), section 'use in specific
      populations', retrieved 2026-08-29
    - When using cabergoline tablets in patients with moderate HI (Child-Pugh B)
      increase monitoring of cabergoline tablets-associated adverse reactions.
      Source: US FDA label for cabergoline (Cabergoline), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary If conception occurs during cabergoline tablets therapy, discontinue
      cabergoline tablets if the risks to the mother or fetus outweigh the benefits to
      the mother.
      Source: US FDA label for cabergoline (Cabergoline), section 'pregnancy', retrieved
      2026-08-29
    - There are risks to the mother associated with the use of cabergoline tablets ( see
      Clinical Considerations ).
      Source: US FDA label for cabergoline (Cabergoline), section 'pregnancy', retrieved
      2026-08-29
    - The estimated background risk of major birth defects and miscarriage in patients
      with hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas
      is unknown.
      Source: US FDA label for cabergoline (Cabergoline), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - However, in another study in rabbits, no treatment-related malformations or
      embryofetal toxicity were observed at doses up to 8 mg/kg/day (approximately 300
      times the maximum recommended human dose). 8.2 Lactation Risk Summary Cabergoline
      tablets are not recommended in postpartum women who are breastfeeding or who are
      planning to breastfeed.
      Source: US FDA label for cabergoline (Cabergoline), section 'use in specific
      populations', retrieved 2026-08-29
    - Avoid use of cabergoline tablets for the inhibition or suppression of physiologic
      lactation [see Indications and Usage ( 1 ) and Warnings and Precautions ( 5 . 4 )]
      . 8.4 Pediatric Use Safety and effectiveness of cabergoline tablets in pediatric
      patients have not been established.
      Source: US FDA label for cabergoline (Cabergoline), section 'use in specific
      populations', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)